



## ***Disclosure of total number of voting rights and number of shares in the capital at March 31, 2009***

Paris, April 7<sup>th</sup>, 2009 – Pursuant to article L.233-8 II of the *Code de commerce* (the French Commercial Code) and article 223-16 of the *Règlement général de l'Autorité des Marchés Financiers* (Regulation of the French stock market authority):

Date	Total number of outstanding shares	Total number of voting rights
March 31, 2009	12, 896,834	Theoretical number of voting rights: 12, 896,834 (including own shares)  Number of real voting rights: 12, 852,090 (without own shares)

### **About BioAlliance Pharma**

BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address drug resistance issues.

### ***BioAlliance Pharma SA***

Dominique Costantini, President and CEO  
Tel.: +33 1 45 58 76 01  
dominique.costantini@bioalliancepharma.com

Nicolas Fellmann, CFO  
Tel.: +33 1 45 58 71 00  
nicolas.fellmann@bioalliancepharma.com

### ***ALIZE RP***

Caroline Carmagnol  
Tel.: +33 6 64 18 99 59  
caroline@alizerp.com